Phase 2 Breast Cancer Trial, Recruiting NCT05292742 Sponsor: Fujian Medical University Union Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05292742
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Women between 18 and 75 years old who have been diagnosed with primary (non-spread) breast cancer
  • People who are generally able to carry out daily activities with little or no limitation (as measured by a standard health performance scale called ECOG, scoring 0 or 1)
  • People whose breast cancer has been confirmed by tissue testing to be invasive, at a stage that has not spread to distant parts of the body (classified as cT1-4/N0-3/M0)
  • People whose breast cancer tests strongly positive for a protein called HER2, confirmed through standard laboratory methods
  • People whose cancer has been tested to determine whether it responds to hormones (ER and PgR status must be known)
  • People who have already received pre-surgery treatment (called neoadjuvant therapy) including at least 9 weeks of a drug called trastuzumab and at least 9 weeks of a type of chemotherapy called a taxane
  • People who still have remaining invasive cancer in the breast (larger than 2 cm) or in underarm lymph nodes after pre-surgery treatment, confirmed by a central laboratory
  • People who are enrolled within 12 weeks of completing surgery (if no radiation was given after surgery), or within 6 weeks of completing post-surgery radiation therapy
  • People whose blood and organ function results fall within the ranges required by the trial, including adequate white blood cell counts, platelet levels, haemoglobin, liver function, kidney function, and heart function (confirm specific values with trial site)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose breast cancer has spread to other parts of the body (Stage IV or metastatic breast cancer)
  • People diagnosed with inflammatory breast cancer
  • People who have previously received anti-cancer treatment or radiation therapy for any other cancer, unless it was a fully cured early-stage skin or cervical cancer
  • People currently receiving anti-cancer therapy in another clinical trial, including certain bone-strengthening drugs or immunotherapy (confirm details with trial site)
  • People who have received any anti-cancer treatment within 28 days before enrolling in the trial
  • People experiencing moderate to severe nerve damage in their hands or feet (Grade 2 or higher on a standard medical scale)
  • People who have received specific targeted therapy drugs that block HER2 signals, including a drug called pyrrolidone or similar medications
  • People who have received high cumulative doses of certain chemotherapy drugs called anthracyclines (specific dose thresholds apply — confirm with trial site)
  • People who have had major surgery unrelated to breast cancer before joining the trial, or who have not fully recovered from such surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

Contact this trial

Phone: 13515020716

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Fujian Medical University Union Hospital
Registry
ClinicalTrials.gov
Start date
2 July 2021
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

iDFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov